GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
1

160 Health International 2656.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

3.46

-1.98%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About 160 Health International

Its shares trade on HKEX under the ticker 2656.HK. It has been listed since 17 September 2025. In the fiscal year to 31 December 2025, it reported revenue of CN¥651.9m and a net loss of CN¥73.0m. At that date it held total assets of CN¥759.9m and shareholders' equity of CN¥239.0m.

160 Health International Ltd is a CN-based company operating in industry. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2025-09-17. 160 Health International Ltd is an investment holding company primarily engaged in pharmaceutical sales. The firm operates two main businesses. Sale of pharmaceutical and healthcare products business, which primarily provides pharmaceuticals to businesses and individuals through wholesale and retail models. Digital healthcare and wellness solutions business primarily provide online marketing solutions, digital hospital solutions, and online healthcare services. The firm also engages in other value-added businesses. The firm operates the Healthcare 160 platform. The firm primarily conducts business in the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
17 Sept 2025
Website
91160.com ↗

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • 160 Health International Ltd operates Healthcare 160 platform for digital healthcare solutions.
  • The company's pharmaceutical sales business serves both wholesale and retail markets in CN.
  • 160 Health International Ltd focuses on domestic market with strong local presence in Shenzhen.

Weaknesses

  • The company's business is primarily limited to the domestic market in CN.
  • 160 Health International Ltd has no international operations or global expansion plans.
  • The firm's reliance on pharmaceutical sales may face market saturation in CN.

Opportunities

  • Expanding digital healthcare solutions through Healthcare 160 platform in CN market.
  • Growing demand for online healthcare services in domestic CN market.
  • Potential for new partnerships in pharmaceutical sales within CN.

Threats

  • Regulatory changes in CN pharmaceutical industry could impact operations.
  • Competition from domestic pharmaceutical companies in CN market.
  • Economic downturn in CN may reduce healthcare spending.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.